Long-term results of the treatment of Hodgkin’s lymphoma in a resource-constrained setting:Real-world data from a single center  

作　　者：Luisa Fernanda Sánchez-Valledor Thomas M Habermann Iván Murrieta-Alvarez Alejandra Carmina Córdova-Ramírez Montserrat Rivera-Álvarez Andrés León-Peña Yahveth Cantero-Fortiz Juan Carlos Olivares-Gazca Guillermo JoséRuiz-Delgado Guillermo JoséRuiz-Argüelles 

机构地区：[1]Escuela de Medicina,Universidad de las Américas Puebla,Cholula 72810,Puebla,Mexico [2]Department of Medicine,Division of Hematology,Mayo Clinical and Mayo Foundation,Rochester,MN 55905,United States [3]Centro de Hematología y Medicina Interna,Clínica Ruiz,Puebla 72530,Mexico [4]Escuela de Medicina,Universidad Popular Autónoma del Estado de Puebla,Puebla 72410,Mexico

出　　处：《World Journal of Clinical Oncology》2021年第9期800-807,共8页世界临床肿瘤学杂志（英文版）

摘　　要：BACKGROUND The outcomes of Hodgkin's lymphoma(HL)in Mexico have not been widely reported.Simplified and affordable treatments have been adopted in middleincome countries.AIM The aim was to evaluate long-used therapies for HL in Mexico in a long-term basis.METHODS In a 34-year time period,88 patients with HL were treated at a single institution in Mexico.Patients were treated with adriamycin bleomycin vinblastine and dacarbazine(ABVD)or mechlorethamine,vincristine,procarbazine,and prednisone(MOPP).Relapsed or refractory patients were given ifosfamide,carboplatin,and etoposide(ICE)followed by autologous or allogeneic stem cell transplants.RESULTS Thirty-seven women and 51 men were included;the median age was 29 years.Patients were followed for a mean of 128 mo.The 310-mo overall survival(OS)was 83%for patients treated with MOPP and 88%for those treated with ABVD.The OS of patients who received autologous stem cell transplantation was 76%(330 mo)vs 93%(402 mo)in those who did not.CONCLUSION HL may be less aggressive in Mexican population than in Caucasians.Combined chemotherapy renders acceptable results,regardless of clinical stage.

关 键 词：HODGKIN LYMPHOMA TREATMENT ABVD chemotherapy 

分 类 号：R733.1[医药卫生—肿瘤]